10-Q: Zimmer Biomet Reports Slight Sales Increase in Q1 2025, Acquisition Costs Expected to Impact Future Earnings

Zimmer Biomet's Q1 2025 net sales rose by 1.1% year-over-year, but the company anticipates lower net earnings for the year due to acquisition and integration costs related to Paragon 28.

Summary

• Zimmer Biomet's net sales for the three months ended March 31, 2025, increased by 1.1% to $1,909.1 million compared to $1,889.2 million in the same period last year.
• The company's net earnings were $182.0 million, up from $172.4 million in the prior year.
• The increase in earnings was primarily due to lower restructuring charges and a net sales increase, offset by higher cost of products sold, increased investments, and higher interest costs.
• The company expects 2025 revenue growth of 5.7% to 8.2%, driven by the Paragon 28 acquisition, market growth, and new product introductions.
• However, net earnings are expected to decrease in 2025 due to acquisition and integration costs, higher manufacturing costs, increased net interest expense, and a higher effective tax rate.
• The company anticipates recognizing $60 million to $80 million of additional expenses related to tariffs in 2025.
• A new global restructuring program, the '2025 Restructuring Plan,' is expected to result in total pre-tax restructuring charges of approximately $85 million.
• The company completed the acquisition of Paragon 28 on April 21, 2025, for approximately $1.4 billion in initial consideration.
• The company paid approximately $1.4 billion in initial consideration and acquisition-related costs to complete the transaction utilizing cash on hand and by borrowing $400.0 million on our 2024 Five-Year Credit Agreement and $150.0 million on our Uncommitted Credit Facility.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While sales and earnings increased, the outlook is tempered by expected decreases in net earnings due to acquisition costs and other factors. The acquisition of Paragon 28 is a positive strategic move, but the associated costs weigh on the overall sentiment.

Positives

• Net sales increased by 1.1% in Q1 2025, driven by market growth, new product introductions, and commercial execution.
• Net earnings increased to $182.0 million in Q1 2025.
• The company expects revenue growth of 5.7% to 8.2% in 2025.
• Cash flows from operating activities were $382.8 million in the three-month period ended March 31, 2025, compared to $228.0 million in the same prior year period.

Negatives

• Net earnings are expected to decrease in 2025 due to acquisition and integration costs, higher manufacturing costs, increased net interest expense, and a higher effective tax rate.
• The company anticipates recognizing $60 million to $80 million of additional expenses related to tariffs in 2025.
• Selling, general and administrative (SG&A) expenses increased in amount and as a percentage of net sales in the three-month period ended March 31, 2025, when compared to the same prior year period.

Risks

• The company faces competition and pricing pressures.
• Dependence on new product development, technological advances and innovation.
• The company's ability to attract, retain, develop and maintain adequate succession plans for the highly skilled employees, senior management, independent agents and distributors we need to support our business.
• The company is exposed to risks related to the ability to realize the anticipated benefits of the acquisition of Paragon 28.
• The company is exposed to risks related to the ability to successfully integrate the operations, products, employees and distributors of acquired companies.
• The company is exposed to risks related to unplanned delays, disruptions and expenses attributable to our enterprise resource planning and other system updates.
• The company is exposed to risks related to dependence on a limited number of suppliers for key raw materials and other inputs and for outsourced activities.
• The company is exposed to risks related to breaches or failures of our (or of our business partners or other third parties) information technology systems or products, including by cyberattack, unauthorized access or theft.
• The company is exposed to risks related to the outcome of government investigations.
• The company is exposed to risks related to the impact of healthcare reform and cost containment measures, including efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, through reductions in reimbursement levels, repayment demands and otherwise.
• The company is exposed to risks related to the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all.
• The company is exposed to risks related to changes in tax obligations arising from examinations by tax authorities and from changes in tax laws in jurisdictions where we do business, including as a result of the base erosion and profit shifting project undertaken by the Organisation for Economic Co-operation and Development and otherwise.
• The company is exposed to risks related to challenges to the tax-free nature of the ZimVie Inc. spinoff transaction and the subsequent liquidation of our retained interest in ZimVie Inc..
• The company is exposed to risks related to the risk of additional tax liability due to the recategorization of our independent agents and distributors to employees.
• The company is exposed to risks related to changes in tariffs relating to imports to the U.S. and other countries.
• The company is exposed to risks related to the risk that material impairment of the carrying value of our intangible assets, including goodwill, could negatively affect our operating results.
• The company is exposed to risks related to changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations.
• The company is exposed to risks related to changes in general industry and market conditions, including domestic and international growth, inflation and currency exchange rates.
• The company is exposed to risks related to the domestic and international business impact of political, social and economic instability, tariffs, trade restrictions and embargoes, sanctions, wars, disputes and other conflicts, including on our ability to operate in, export from or collect accounts receivable in affected countries.
• The company is exposed to risks related to challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration ('FDA') and other government regulators relating to medical products, healthcare fraud and abuse laws and data privacy and cybersecurity laws.
• The company is exposed to risks related to the success of our quality and operational excellence initiatives.
• The company is exposed to risks related to the ability to remediate matters identified in inspectional observations issued by the FDA and other regulators, while continuing to satisfy the demand for our products.
• The company is exposed to risks related to product liability, intellectual property and commercial litigation losses.
• The company is exposed to risks related to the ability to obtain and maintain adequate intellectual property protection.

Future Outlook

The company expects revenue growth in 2025, driven by the Paragon 28 acquisition and market growth, but anticipates lower net earnings due to acquisition costs, higher manufacturing costs, and increased interest expense.

Industry Context

The medical device industry is experiencing ongoing consolidation, with companies seeking to expand their product portfolios and market reach through acquisitions. Zimmer Biomet's acquisition of Paragon 28 reflects this trend, as it aims to strengthen its position in the foot and ankle orthopedic segment.

Comparison to Industry Standards

• Stryker, a major competitor in the orthopedic space, also pursues growth through acquisitions and new product development.
• Similar to Zimmer Biomet, Stryker faces challenges related to pricing pressures and healthcare cost containment.
• Medtronic, another key player, focuses on innovation and strategic partnerships to maintain its competitive edge.
• Globus Medical is a smaller but rapidly growing competitor known for its focus on spinal implants and enabling technologies.
• Zimmer Biomet's performance is benchmarked against these companies to assess its relative growth, profitability, and market share.

Management Changes

Legal Proceedings

• The company is involved in various legal proceedings, including product liability, intellectual property, stockholder matters, tax disputes, commercial disputes, employment matters, whistleblower and qui tam claims and investigations, governmental proceedings and investigations, and other legal matters that arise in the normal course of our business.
• The IRS has proposed adjustments for tax years 2013-2015 and 2016-2019, which the company intends to contest vigorously.
• Paragon 28 is subject to a securities class action lawsuit and an SEC subpoena related to previously issued financial statements.

Stakeholder Impact

• Shareholders may experience short-term dilution due to the costs associated with the Paragon 28 acquisition, but could benefit from long-term growth.
• Employees may be affected by the ongoing restructuring plans.
• Customers may benefit from the expanded product portfolio and integrated solutions resulting from the acquisition.
• Suppliers may see increased demand for certain products and services.
• Creditors should be aware of the increased debt levels following the acquisition.

Next Steps

• Continue executing on the 2025, 2023, and 2019 Restructuring Plans.
• Integrate Paragon 28 into Zimmer Biomet's operations.
• Manage costs and expenses to mitigate the impact of tariffs and other headwinds.
• Vigorously contest the IRS's proposed adjustments for tax years 2013-2019.

Key Dates

Keywords

Zimmer Biomet, orthopedic, medical devices, financial results, Q1 2025, Paragon 28, acquisition, restructuring, sales, earnings